Tel.: +34 91 736 2385
LOCAL TIME
Contact: Katarina Gluic
Hours: Mon-Thu 8:30-17:00 Fri 8:30-15:00
20:54
For help with a poster, please specify the poster number, the first author and the congress and we will reply shortly.
Poster no.
Contact name
E-mail
Telephone
Congress
Comments

 

International Liver Cancer Association 14th Annual Conference

 

September 11-13, 2020 Virtual Conference
FAQs
   
Discussion forum - International Liver Cancer Association 20th Annual Conference
    Topic - Clinical Trials in progress

If you are already registered in PosterSessionOnline, enter your e-mail and click on LOGIN. Otherwise click on REGISTER.
 

Poster: 3
Visits: 186
Title: Ramucirumab For Patients With Advanced Hepatocellular Carcinoma And Elevated Alpha Fetoprotein Following A Non-Sorafenib Based Systemic Therapy: Interim Results From An Expansion Cohort Of The Phase 3 Reach-2 Study
Authors: David Mcilwain ,
Centre: 

You must be registered to reply or comment.

RAMUCIRUMAB FOR PATIENTS WITH ADVANCED HEPATOCELLULAR CARCINOMA AND ELEVATED ALPHA FETOPROTEIN FOLLOWING A NON-SORAFENIB BASED SYSTEMIC THERAPY: INTERIM RESULTS FROM AN EXPANSION COHORT OF THE PHASE 3 REACH-2 STUDY

Cristina Miralles
Thread initiator
Subspeciality
Reg: 12/12/2019 1:08:00 PM

Comment# 1

I invite healthcare professionals to open debate around the issues raised in my poster, both those relating to research and to clinical practice.

Comment added on 9/22/2020 1:28:00 PM 
     
You must be registered to reply or comment.



Most viewed poster for this congress
Poster: 1
Visits: 241
Title: Pembrolizumab In Combination With Gemcitabine And Cisplatin For The Treatment Of Advanced Biliary Tract Cancer: Phase 3 Keynote-966 Trial In Progress
Authors: Robin Kelley , R.K. KELLEY, A. VOGEL, R.S. FINN, J. FURUSE, J. EDELINE, Z. REN, S.-C. SU, U. MALHOTRA, A.B. SIEGEL, J.W. VALLE
Centre: 

Poster most viewed in this topic
Poster: 3
Visits: 186
Title: Ramucirumab For Patients With Advanced Hepatocellular Carcinoma And Elevated Alpha Fetoprotein Following A Non-Sorafenib Based Systemic Therapy: Interim Results From An Expansion Cohort Of The Phase 3 Reach-2 Study
Authors: David Mcilwain ,
Centre: 


 




PosterSessionOnline
Logo Draft
 
Logo Cert